Argenx (ARGX)
(Delayed Data from NSDQ)
$536.70 USD
+9.45 (1.79%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $536.78 +0.08 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$536.70 USD
+9.45 (1.79%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $536.78 +0.08 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth D Momentum F VGM
Zacks News
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
GSK Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
by Zacks Equity Research
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
by Zacks Equity Research
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
by Zacks Equity Research
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?
by Zacks Equity Research
Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect increasing patient days and admissions.
Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results are likely to reflect improved performances from the Acute Care Hospital Services and Behavioral Health Care Services businesses.
How Argenx (ARGX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
by Zacks Equity Research
Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study
by Zacks Equity Research
argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
by Zacks Equity Research
Halozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected second-quarter 2023 results, boosted by collaboration and royalty revenues. Management raises its 2023 guidance.
Biotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety Issues
by Zacks Equity Research
Regulatory and key pipeline updates from BridgeBio (BBIO) and argenx (ARGX) are in focus in the biotech sector.
Halozyme Therapeutics (HALO) Soars 5.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Halozyme Therapeutics (HALO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
argenex SE (ARGX) Surges 27.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
argenex SE (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
All You Need to Know About argenex SE (ARGX) Rating Upgrade to Buy
by Zacks Equity Research
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Editas (EDIT) Soars 20.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Geron (GERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on updates on Geron's (GERN) lead pipeline candidate when it reports its fourth-quarter earnings.
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance
by Zacks Equity Research
Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.
argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why
by Zacks Equity Research
Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.